Last reviewed · How we verify

NCT06668012: DISPALOMA

A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)

Recruiting now NA Last updated 3 February 2025
What this trial tests

NA trial testing Palomacare® vaginal gel is a medical device with CE class IIa. in Vaginal Dysbiosis in 30 participants. Currently enrolling.

Timeline
12 December 2024
Primary endpoint
20 May 2025
31 May 2025

Quick facts

Lead sponsorProcare Health Iberia S.L.
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment30
Start date12 December 2024
Primary completion20 May 2025
Estimated completion31 May 2025
Sites2 locations across Spain

Drugs / interventions tested

Conditions studied

Sponsor

Procare Health Iberia S.L. — full company profile →

Who can join

Adults 18 to 45, female only, with Vaginal Dysbiosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis is raised of improving the status of vagnal microbiota with a non-hormonal topical product in early situations of dysbiosis in which the vaginal pH is elevated and the patient may or may not be symptomatic, in order to try to prevent the appearance of future established vaginal infections.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Procare Health Iberia S.L. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06668012.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing